Welcome to our dedicated page for Pharming Group N.V. news (Ticker: PHAR), a resource for investors and traders seeking the latest updates and insights on Pharming Group N.V. stock.
Pharming Group N.V. ADS (PHAR) generates a steady flow of news related to rare disease biopharmaceuticals, including commercial updates, clinical trial milestones, regulatory decisions, and financial results. As a global company focused on hereditary angioedema (HAE) and activated phosphoinositide 3‑kinase delta syndrome (APDS), its announcements often center on RUCONEST for acute HAE attacks and Joenja (leniolisib), an oral PI3Kδ inhibitor for APDS.
Investors following PHAR news can expect regular updates on regulatory progress for leniolisib, such as U.S. FDA approvals, Priority Review designations, and submissions in regions including the European Economic Area, the U.K., Japan, and other markets. Pharming also reports on Phase III pediatric trials of leniolisib in children with APDS and Phase II studies in broader primary immunodeficiency populations, as well as scientific publications that refine APDS diagnosis through genetic variant classification.
Company communications frequently include commercial performance highlights, with quarterly and half‑year financial reports detailing revenue contributions from RUCONEST and Joenja, geographic breakdowns, and commentary on patient and prescriber trends. Pharming also issues news about participation in healthcare and investor conferences, scientific meetings, and presentations of new data on HAE and APDS.
For readers tracking PHAR, this news stream provides insight into how Pharming is advancing its rare disease portfolio, expanding access to Joenja and RUCONEST, and executing on its strategy as a dual‑listed mid‑cap biopharmaceutical company. Bookmarking the news page allows investors, analysts, and healthcare professionals to monitor key catalysts, including clinical readouts, regulatory milestones, and major corporate developments disclosed in press releases and Form 6‑K filings.
Pharming Group N.V. has received a positive decision from the UK's MHRA regarding its Paediatric Investigation Plan (PIP) for leniolisib, aimed at treating activated phosphoinositide 3-kinase delta syndrome (APDS) in children aged 1 to under 18. Additionally, leniolisib has been granted Promising Innovative Medicine (PIM) designation, enabling potential access through the MHRA's Early Access to Medicines Scheme. The PIP includes two planned global clinical trials, with recruitment expected to begin in the second half of 2022. Pharming aims to file for global registration and launch leniolisib in the US and Europe in 2023.
Pharming Group N.V. announced positive data from the Phase II/III trial of leniolisib for activated phosphoinositide 3-kinase delta syndrome (APDS) at the Clinical Immunology Society (CIS) 2022 Annual Meeting. The trial met its co-primary endpoints, showing a significant reduction in lymph node size and an increase in naive B cells among treated patients. The study drug was well-tolerated with no treatment-related serious adverse events. Pharming plans to submit global regulatory filings for leniolisib in Q2 2022 and aims for U.S. and European launches in 2023.